Clinical Trial

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies the effect of talazoparib with androgen deprivation therapy and abiraterone in treating castration sensitive prostate cancer patients. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Androgen can cause the growth of prostate tumor cells. Degarelix, leuprolide acetate, bicalutamide, goserelin acetate, and abiraterone lowers the amount of androgen made by the body. This may help stop the growth of tumor cells that need androgen to grow. Giving talazoparib with androgen deprivation therapy and abiraterone may improve cancer control for patients with castration sensitive prostate cancer.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-01-28; most recent amendment 2026-01-27.
Status change: Active, Not Recruiting → Recruiting 2022-10-07
Status change: Recruiting → Active, Not Recruiting 2022-09-28
Status change: Not Yet Recruiting → Recruiting 2021-08-10
Trial Details
NCT Number NCT04734730
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Enrollment 70 participants
Start Date 2021-05-04
Primary Completion 2027-08-23 (estimated)
Study Completion 2027-08-23 (estimated)
Updated on ClinicalTrials.gov 2026-01-28